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Toll-like receptors (TLRs) are evolutionarily conserved pathogen sensors that constitute the
first line of defense in the human immune system. Herpesviruses are prevalent throughout
the world and cause significant disease in the human population. Sensing of herpesviruses
via TLRs has only been documented in the last 10 years and our understanding of the
relationship between these sentinels of the immune system and herpesvirus infection
has already provided great insight into how the host cell responds to viral infection. This
report will summarize the activation and modulation of TLR signaling in the context of
human herpesvirus infections.
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INTRODUCTION
Pathogen detection is critical in the establishment of an immune
response by the host innate immune system. Recognition of
microbial pathogens is primarily carried out by cell surface or
endosomal receptors, which trigger signaling cascades that result
in the upregulation of inflammatory cytokines and type I inter-
feron (IFN) (Akira and Sato, 2003; Akira and Takeda, 2004).
One of the key innate immune receptors, Toll receptors, was first
identified in Drosophila Melanogaster as being responsible for
detection of fungal infection. Subsequently, eleven homologs of
the Drosophila Toll receptors have been identified in humans and
are classified as Toll-like receptors (TLRs) (Akira et al., 2001).
TLRs represent the first line of defense in the human innate
immune response and consequently have become an intense focus
of study in the response to virus infection. Understanding the role
of TLRs during pathogen infection and the signaling events that
occur in response to stimulation of TLRs helps to provide a clearer
picture of the establishment of the innate immune response to
viral infection.
TLRs are termed pattern recognition receptors (PRRs), a gen-
eral name for a family of receptors capable of recognizing a wide
variety of pathogen associated molecular patterns (PAMPs) (Slack
et al., 2000). PAMPs are motifs common to large numbers of
pathogens, which upon detection by TLRs leads to initiation of
TLR signaling cascades, launching the host immune response
(Akira and Hemmi, 2003). TLRs are type I membrane proteins
that recognize their ligands via leucine rich repeat (LRR) motifs
contained within their Ig-like ectodomains (Slack et al., 2000;
Akira and Hemmi, 2003; Akira and Sato, 2003). Currently, eleven
mammalian TLRs have been identified, however, only nine have
been well characterized. TLR expression is cell type dependent
and most cells express at least a small complement of TLRs.
The location of TLRs in the cell aids in their ability to rec-
ognize a wide variety of invading pathogens. TLRs 1, 2, 4, 5,
and 6 sense pathogens at the cell surface, while TLRs 3, 7, 8,
and 9 are located on endosomal membranes and serve primar-
ily as nucleic acid sensors (Akira et al., 2001; Akira and Sato,
2003; Akira and Takeda, 2004). This review will focus on the
activation of TLR signaling in response to human herpesviruses
infection.
The agonists have been identified for nine of the eleven mam-
malian TLRs, including each of the endosomal TLRs. TLR3 senses
double-stranded RNA, a common intermediate in virus infection.
Human TLR7 and TLR8 appear to have redundant functions,
and recognize single-stranded RNA, another common interme-
diate during viral infection (Akira et al., 2001; Alexopoulou et al.,
2001; Akira and Hemmi, 2003; Kariko et al., 2004a,b; Sarkar et al.,
2004, 2007; Sen and Sarkar, 2005; Carpentier et al., 2007). TLR9
has been shown to bind CpG unmethylated DNA, a common
sequence motif in DNA viruses but a relatively rare sequence in
vertebrates (Hemmi et al., 2000; Bauer et al., 2001; Akira and
Hemmi, 2003).
TLR signaling is mediated through one of two adapter pro-
teins, MyD88 or TRIF. All TLRs, with the exception of TLR3
and one arm of the TLR4 pathway, initiate signaling via MyD88.
TLR3 signals through the adapter protein TRIF (Kawai and Akira,
2006). TLR4 is capable of signaling through both MyD88 depen-
dent and independent pathways (Kawai et al., 2001). Activation of
the TLR response results in a signaling cascade generated to sup-
press and eradicate the invading pathogen. Increased production
of inflammatory cytokines such as IL-6, type I IFN, a key compo-
nent of the anti-viral state, and secretion of chemokines to attract
innate immune cells, including neutrophils andmacrophages, are
all consequences of TLR activation (Akira and Takeda, 2004).
Figure 1 summarizes human herpesvirus activation of TLR sig-
naling. Herpesviruses are well known for their ability to control
the host immune response in order to achieve latency (Damania,
2004; Melroe et al., 2004; Paladino and Mossman, 2009; Paludan
et al., 2011). Therefore, activation of TLR signaling is often coun-
tered by the virus using viral encoded suppressors of host immune
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FIGURE 1 | Human herpesviruses can stimulate a wide variety of TLRs
leading to upregulation of both inflammatory cytokines and type I
interferon. (A) Activation of NF-κB and inflammatory cytokines (IL-6, IL-8, and
IL-12) via TLR stimulation by human herpesviruses. TLR stimulation results in
activation of NF-κB in the cytoplasm and subsequent translocation to the
nucleus where it serves as a transcriptional activator for a large number of
inflammatory cytokines. Activation of these cytokines can occur after
stimulation of both endosomal and cell surface TLRs by human herpesviruses.
(B) Activation of type I interferon in response to recognition of human
herpesviruses by TLRs. Both IFN-α and IFN-β are activated by cellular interferon
regulatory factors (IRFs), specifically IRF3 and IRF7, which translocate to the
nucleus following phosphorylation and activate the IFN-α and IFN-β
promoters. Activation of type I interferon are induced after stimulation of both
cell surface TLRs (TLR2 and TLR4), and endosomal TLRs (TLR3, 7, and 9).
proteins, some targeted specifically to TLR signaling pathways.
For each of the viruses discussed in this review we will also high-
light viral proteins known to inhibit different aspects of TLR
signaling.
α-HERPESVIRUSES
HERPES SIMPLEX VIRUS—TYPES 1 & 2
Human herpesviruses 1 and 2, more commonly known as herpes
simplex types 1 and 2 (HSV-1 and HSV-2) are present in approxi-
mately 80% of the human population (Cunningham et al., 2006).
Initial infection occurs either on the skin or in the oral or genital
mucosa. Latent infection is established in cell bodies of neurons
where the virus permanently resides in the host. HSV-1 infection
can result in ocular herpes (which can lead to blindness), gen-
ital herpes, and encephalitis (most common in young children)
(Cunningham et al., 2006). HSV-2 infection is the leading cause
of genital herpes, which can lead to neonatal herpes, and infec-
tion with HSV-2 increases the likelihood of acquiring HIV almost
3 fold (Wald and Link, 2002; Cunningham et al., 2006).
Cytokine production as a result of TLR stimulation typically
leads to virus clearance or aids in the control of viral spread
via establishment of an anti-viral state through activation of IFN
and recruitment of innate and adaptive immune cells to the site
of infection. However, in some cases the release of cytokines
following virus infection can have a detrimental effect on the
host. In 2004, Kurt-Jones et al. reported that HEK293 cells con-
stitutively expressing TLR2 showed increased IL-6 production
in response to primary HSV-1 infection, and that this increase
could be attributed to activation of NF-κB (Kurt-Jones et al.,
2004). This report went on to demonstrate that while TLR2
does play an important role in recognition of HSV-1, it also
contributes to encephalitis in infected mice. Wild type mice,
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TLR2−/−, and TLR4−/− mice were challenged with equivalent
amounts of HSV-1 via intraperitoneal injection. Significantly
fewer mice succumbed to infection from the TLR2−/− group
and symptoms of disease were also reduced in TLR2−/− mice
compared to both wild type and TLR4−/− mice, serum levels
of IL-6 were significantly reduced in TLR2−/− mice (Kurt-Jones
et al., 2004). Because neonates are extremely susceptible to HSV-
1 infection, neonatal mice were also challenged with HSV-1
and monitored for disease progression and symptoms. By day
6 post-infection, 90% of the wild type and TLR4−/− mice had
succumbed to infection, while over 60% of the TLR2−/− mice
survived and half of the survivors were symptom free through-
out the study (Kurt-Jones et al., 2004). The authors attributed
the survival of TLR2−/− mice to the reduction in cytokine lev-
els and accompanying inflammation in the brain of the infected
animals.
The inflammatory responses among the different mouse
groups varied drastically and indicated that TLR2-mediated
cytokine responses to HSV-1 infection can be lethal inmice (Kurt-
Jones et al., 2004). Elevated levels of IL-6 and CCL2were detected
in the serum and brain, respectively, compared to the levels in
wild type and TLR4−/− mice. Inflammatory lesions were also
observed in the brains of infected wild type and TLR4−/− mice,
but not in the brains of TLR2−/− mice, despite similar virus titers
in the brain (Kurt-Jones et al., 2004). This report suggests that
the host response may contribute to the pathogenesis of HSV-1
infection, as much or sometimes more so than the virus infection
itself.
A role for an additional TLR, TLR9, was also identified in
HSV-1 infection of mice (Krug et al., 2004). Initially, CD11c+
splenocytes from wild type and MyD88 deficient mice were
infected with HSV-1 via corneal infection and levels of IFN-
α and IL-12 were measured. Both IFN-α and IL-12 levels were
reduced in MyD88 deficient mice compared to wild-type con-
trols. Plasmacytoid dendritic cells (pDCs) were then sorted from
the CD11c+ population from both wild type and MyD88−/−
mice and were exposed to HSV-1. IFN-α and IL-12 levels were
significantly increased compared to wild type controls (Krug
et al., 2004). To determine whether TLR9 was responsible for
the cytokine upregulation, pDCs were isolated from TLR9−/−
mice and infected with HSV-1. pDCs from TLR9 deficient mice
displayed significantly less IFN-α activation along with reduced
levels of IL-12 secretion. pDCs from TLR9−/− mice also showed
reduced levels of the activation marker CD86 compared to wild
type controls. To confirm the specificity for TLR9, pDCs were
infected in the presence of a TLR9 competitive inhibitor (ODN,
2088). In the presence of the inhibitor, HSV-1 infected pDCs
from wild type animals showed lower levels of IFN-α and IL-12
and also reduced expression of CD86 (Krug et al., 2004) indi-
cating that the recognition of HSV-1 is specific for TLR9 in
murine pDCs.
Because HSV-1 resides in neurons during latency, cells within
the brain that can mediate immune responses are key in con-
trolling HSV infection and spread. Microglial cells are the
macrophages of the brain; they sense invading pathogens and are
critical in mounting proper immune responses within the brain
(Aravalli et al., 2005). HSV infection of primary microglial cells
isolated from wild type and TLR2−/− mice revealed that TLR2
activation by HSV was required for the secretion of a wide vari-
ety of cytokines and chemokines including, IL-6, IL-12, CCLl7,
CCL8, CCL9, CXCL1, CXCL2, CXCL4, CXCL5, IL-1β, and TNF-α
(Aravalli et al., 2005).
HSV-1 infection can result in corneal keratitis following
infection of the epithelial and stromal layers of the cornea
(Li et al., 2005). It has been determined using human corneal
epithelial cells, both immortalized cells (HUCL) and primary
cells (HCECs), that TLR7 is induced upon HSV-1 infection while
TLR3 is down regulated (Li et al., 2005). Infection of human
corneal epithelial cells resulted in activation of multiple tran-
scription factors including NF-κB, JNK, and p38 (Li et al., 2005).
Activation of each of these factors occurred in two distinct peaks,
first at 1–4 h post-infection and again at 8 h post-infection. Each
peak could be further differentiated based on activation of a
unique set of secondary factors. During the first peak activa-
tion (1–4 h), upregulation of several cytokines was also observed
including IL-6, IL-8, TNF-α, and IFN-β. Concomitant with the
second peak of activation (8 h), two significant changes in TLR
expression were observed (Li et al., 2005). TLR7 levels were
increased and TLR3 levels were decreased. The authors concluded
that sequential regulation of these two TLRs was necessary for a
proper immune response in epithelial cells.
In 2006, it was discovered that subpopulations of the KOS
strain of HSV-1 and two strains of HSV-2, WT186 (186-K)
and unique long region 29-deficient 186 strain (UL29−186-K),
could activate TLR2 signaling based on NF-κB reporter assays.
Activation of TLR2 also led to increased secretion of both IL-
6 and IL-12 (Sato et al., 2006). This study also showed that
activation of TLR9 by these subpopulations of HSV-1 and HSV-
2 could occur in the same cell that had already recognized
these incoming pathogens via TLR2. The activation of TLRs
was sequential and the results suggested a new mechanism by
which an invading pathogen could trigger TLR signaling via
two distinct TLR pathways within the same cell (Sato et al.,
2006).
There are conflicting reports in the literature about the
activation of TLR2 by HSV-1 viral glycoproteins. It was ini-
tially reported that HSV-1 entry glycoproteins could be recog-
nized by monocyte derived dendritic cells (Reske et al., 2008).
Recognition of gB, gD, and gH/gL resulted in upregulation of
CD40, CD83, CD86, IL-10, and IFN-α in these cells, however,
the observed changes in each of these downstream inflammatory
proteins was not dependent on binding of these viral glycopro-
teins to surface expressed TLR2 (Reske et al., 2008). However, a
more recent report suggests that gB and gH/gL are both capa-
ble of binding TLR2 and that a soluble form of the gH/gL
complex alone is sufficient to induce upregulation of NF-κB
(Leoni et al., 2012). Immune precipitation was used to identify
which glycoprotein complexes were sufficient for binding TLR2;
gH/gL and gB could each bind TLR2 while gD was not able
to bind.
Deletion or mutation of a pathogen sensor, e.g., a TLR, can
have significant effects on the ability of a host to mount a proper
immune response to pathogen infection. Two reports have iden-
tified defects in TLR3 expression/function that are critical to
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the development of HSV encephalitis (Zhang et al., 2007; Guo
et al., 2011). Two patients suffering from HSV encephalitis were
determined to have identical mutations in TLR3. The mutation
(cytosine → thymine) at nucleotide 1660 resulted in an amino
acid substitution (proline → serine) at position 554. Mutation
at this position is thought to affect binding of the cognate ligand,
dsRNA, to TLR3. Fibroblasts harvested from each patient showed
a decreased ability to respond to the dsRNA mimic polyinosine-
polycytidylic acid [poly(I:C)] (Zhang et al., 2007). IFN-β and IL-6
expression were both decreased in response to poly(I:C) in cells
isolated from TLR3 deficient patients compared to cells isolated
from healthy donors not harboring the mutation (Zhang et al.,
2007). NF-κB and IRF3 expression were also impaired when com-
pared to fibroblasts from healthy donors. Interestingly, however,
PBMCs isolated from these patients showed normal produc-
tion of IFN-α when challenged with a wide array of viruses,
both RNA and DNA viruses (Zhang et al., 2007). The defect
in immune response seemed to be specific to only HSV-1 and
vesicular stomatitis virus (VSV) in fibroblasts. Additionally, five
patients carrying the mutation did not develop HSV encephali-
tis. These last two points indicate the need for more studies into
the role of TLRs in disease progression and the need for a clearer
understanding of the possible redundancy within the TLR family.
Herpes simplex virus (HSV-2) was one of the first her-
pesviruses shown to activate TLR signaling. Infection of mouse
bone marrow cells, which contain a high percentage of pDCs,
with both live HSV-2 and UV-inactivated HSV-2 showed signif-
icantly increased IFN-α production (Lund et al., 2003). It was
also determined that the adapter protein MyD88 was required for
IFN-α production. HSV-2 DNA was recognized by TLR9 and an
intact endocytic pathway was required for TLR9 mediated IFN-α
production (Lund et al., 2003).
Another recent report has shown that HSV-2 can activate
both TLR4 and TLR9 signaling in human cervical epithelial cells
(HCE) (Li et al., 2009). In vitro infection of human cervical
epithelium with HSV-2 resulted in increased levels of TLR4 and
TLR9 mRNA and a concomitant increase in protein expression
for each TLR. NF-κB was also induced as a result of infection
with HSV-2 and its expression could be augmented with co-
transfection of a TLR4 expression construct. IL-6 and IFN-β
levels were also increased following HSV-2 infection of HCE cells
(Li et al., 2009).
HSV encoded antagonists of TLR signaling and interferon
activation
HSV encodes several proteins that can inhibit downstream sig-
naling following TLR activation. The immediate early protein,
ICP0, encoded by HSV-1 induces the degradation of MyD88 and
its adaptor protein, TIRAP/MAL (Van Lint et al., 2010). Another
HSV-1 encoded protein, the virion host shut-off protein (VHS)
which has endonuclease activity, is thought to inhibit TLR3 sig-
naling in conventional DCs since VHS deficient viruses could
induce much higher pro-inflammatory cytokines from these cells
(Cotter et al., 2010). The principal downstream target of TLR sig-
naling is the induction of type I IFN through activation of IRFs.
ICP0 is an E3 ubiquitin ligase that can either bind to IRF3 or
degrade it and prevent its ability to activate IFN, or prevent the
accumulation of IRF3 in the nucleus (Melroe et al., 2004, 2007;
Paladino et al., 2010).
VARICELLA ZOSTER VIRUS
Primary infection with varicella zoster virus (VZV) also known
as human herpesvirus 3 (HHV-3) results in varicella, commonly
known as chicken pox [reviewed in Gershon et al. (2010)]. Once
the initial infection has been cleared by the host immune sys-
tem the virus enters a latent state in both neurons and spinal
dorsal root ganglia. Upon reactivation VZV presents as herpes
zoster, or shingles, this infection is usually cleared by the host;
however, complications such as post-herpetic neuralgia can arise,
most often in immune compromised individuals (Gershon et al.,
2010). The virus can re-enter latency following the clearance of
shingles and continue to persist in the host. IFN production in
response to VZV infection has been observed, as has inflamma-
tory cytokine production (Arvin et al., 1986; Torigo et al., 2000).
Both of these characteristics of VZV infection are hallmarks of
TLR activation.
In 2005, Wang et al. described activation of TLR2 upon infec-
tion of monocytes and macrophage with VZV. The response was
characterized by induction of the inflammatory cytokine IL-6
mediated by activated NF-κB (Wang et al., 2005b). Specific inhi-
bition of TLR2 using siRNA resulted in decreased levels of IL-6
suggesting a specific upregulation of TLR2 on monocytes and
macrophage subsequent to VZV infection. UV-inactivated VZV
also led to increased IL-6 production.
Primary infection with VZV activates TLR9 in pDCs leading to
increased IFN-α production (Yu et al., 2011). Purified pDCs were
infected with live or UV-inactivated VZV and IFN-α levels were
measured by ELISA. pDCs infected with live VZV showed strong
induction of IFN-α, while pDCs infected with UV-VZV showed
reduced levels of IFN-α. It was determined by treating pDCs with
specific inhibitors of TLR9 that a majority of the IFN-α response
was due to activation of TLR9 signaling (Yu et al., 2011). The
reduced levels of IFN-α observed following infection with UV-
VZV might occur through a TLR9-independent mechanism of
IFN-α induction, perhaps through the RNA dependent protein
kinase (PKR), which was activated following VZV infection and
played a role in IFN-α production (Yu et al., 2011).
There is recent evidence that DCs infected with a clinical iso-
late of VZV (JoSt) respond differently to TLR2 stimulation than
DCs infected with the vaccine strain of VZV (V-Oka) (Gutzeit
et al., 2010). DCs infected with the JoSt strain of VZV and stim-
ulated with lipoteichoic acid (LTA), a TLR2 agonist, secreted dra-
matically less IL-12 than DCs infected with the vaccine strain and
challenged with the same TLR2 agonist (Gutzeit et al., 2010). IL-
12 secretion from DCs is critical for the development of adaptive
immune responses to infection. Therefore, the fact that virulent
VZV (JoSt) blocks this secretion suggests a mechanism through
which the virus is able to evade the adaptive immune response. It
also highlights why the vaccine strain is effective in mounting an
antiviral response (Gutzeit et al., 2010).
VZV encoded antagonists of TLR signaling and interferon activation
Currently, roles for two VZV viral proteins have been identi-
fied. The VZV kinase, Orf47p, has been shown to induce an
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atypical phosphorylation event on IRF3 that is inhibitory and
prevents IRF3 homodimerization and induction of type I IFN
(Vandevenne et al., 2011). Another viral protein, IE62, was shown
to prevent TBK1-mediated activation of IFN-β expression. IE62
also inhibited IRF3 function by blocking phosphorylation of IRF3
at sites that are needed for activation (Sen et al., 2010). Inhibition
by these two viral proteins would significantly affect the ability of
the host to mount TLR driven immune responses following virus
infection.
β-HERPESVIRUSES
HUMAN CYTOMEGALOVIRUS
In 2003, human cytomegalovirus (HCMV), also known as human
herpesvirus 5 (HHV-5) was the first herpesvirus shown to trigger
TLRmediated signaling events (Compton et al., 2003). CMV acti-
vates TLR2, leading to NF-κB-mediated upregulation of inflam-
matory cytokines. Both IL-6 and IL-8 were increased following
infection of human PBMCs with CMV. PBMCs infected with UV-
inactivated CMV also showed increased IL-6 and IL-8 secretion
indicating no requirement for replication competent viral parti-
cles to stimulate this response (Compton et al., 2003). HEK293
cells stably expressing either TLR2 or TLR4 were infected with
CMV and analyzed for production of IL-8 (Compton et al., 2003).
Only infection of TLR2 expressing cells resulted in increased
IL-8 secretion. It was also determined that TLR2 activation
of inflammatory cytokines is mediated through NF-κB activa-
tion. Additionally, thioglycolate-elicited peritoneal macrophages
(PECs) were isolated from wild type, TLR4−/−, and TLR2−/−
mice and infected with CMV. PECs from TLR4−/− mice showed
normal IL-6 production in response to CMV infection, while
PECs from TLR2−/− secreted no detectable IL-6. PECs from
both knockout mice responded normally to their cognate ligands
(zymosan/TLR2 and LPS/TLR4) (Compton et al., 2003). These
results indicate that IL-6 upregulation following CMV infection
of PECs is mediated specifically through TLR2, because even in
the presence of functional TLR4 (TLR2−/− mice) there was no
detectable IL-6 in response to CMV infection (Compton et al.,
2003).
In 2006, continued study into the activation of the innate
immune response to CMV revealed that two viral proteins were
responsible for TLR2 recognition, the glycoproteins gB and gH
(Boehme et al., 2006). gB and gH are required for TLR2 recogni-
tion of CMV and both proteins co-immunoprecipitate with TLR1
and TLR2. Pre-treatment of UV-inactivated CMV particles with
antibodies against gB and gH prior to infection of human fibrob-
lasts resulted in a 40–50% reduction in secreted IL-6, confirming
the importance of the recognition of gB and gH by TLR2 during
CMV infection (Boehme et al., 2006).
Recently, HCMV infection has been shown to result in upreg-
ulation of TLR2, TLR3, and TLR9 in monocytes in the presence
of the human monocyte scavenger receptor A type 1 (SR-A1)
(Yew et al., 2010). TLR2, Lyn kinase and the p35 subunit of IL-12
were all upregulated within 10min of HCMV infection in THP-
1 monocytes. TLR3 and TLR9 levels were increased after 1 hr of
HCMV infection (Yew et al., 2010). This is evidence of activation
of multiple TLR pathways in a single cell. This group later showed
that blocking Lyn kinase, which is associated with SR-A1, leads to
inhibition of TLR9 signaling and shifts the response to a primar-
ily TLR3 driven IFN-β response but also a non-canonical TLR3
driven NF-κB response (Yew and Harrison, 2011).
CMV encoded antagonists of interferon and chemokine induction
The immediate-early 2 gene product IE86 has been identified
as an inhibitor of both IFN-β production and chemokine pro-
duction. Initially, IE86 was identified as being able to block
IFN-β production following both HCMV infection and Sendai
virus infection (Taylor and Bresnahan, 2005). Soon thereafter the
same lab determined that HCMV IE86 can also block chemokine
induction, including IL-8, CCL5, CCL3, and CCL8 after HCMV
and Sendai virus infection (Taylor and Bresnahan, 2006b). Each
of these chemokines can be induced following activation of TLR
signaling. Lastly, a mechanism of action for IE86 was discovered,
possibly explaining the ability of IE86 to have such a dramatic
effect on the levels of immune response genes following virus
infection. IE86 inhibits NF-κB transcriptional activation by pre-
venting binding of NF-κB to DNA, specifically to the IFN-β
promoter (Taylor and Bresnahan, 2006a). IE86 was also shown
to be critical for TNF-α driven NF-κB transcription of both CCL5
and IL-8 (Taylor and Bresnahan, 2006a).
HUMAN HERPESVIRUS-6 (6A AND B)
Human herpesvirus-6 is a ubiquitous human virus infecting over
90% of the world’s population (Chi et al., 2012). The most com-
mon outcome of HHV-6 infection is exanthem subitmum, also
known as “roseola.” HHV-6 was initially isolated from the blood
of patients with lymphoproliferative disorders, including AIDS
(Salahuddin et al., 1986).
Recently a role for TLR activation has been uncovered follow-
ing infection of CD4+ T cells with HHV-6A (GS strain) (Chi
et al., 2012). This study revealed that HHV-6A infection of CD4+
T cells resulted in the upregulation of TLR9 mRNA and protein
levels. HHV-6A infection also led to activation of JNK andMAPK
signaling pathways, including increased levels of phosphorylated
JNK (Chi et al., 2012). Increased secretion of IL-6 and TNF-αwas
also secreted following HHV-6A infection.
A second recent report suggests that upon stimulation with
TLR ligands, cells infected with HHV-6B show decreased levels of
cytokine production in response to ligand treatment (Murakami
et al., 2010). In this study HHV-6B infected dendritic cells were
stimulated with ligands against TLR3 [poly(I:C)], TLR4 (LPS),
and TLR7 (imidazoquinoline). In each case treatment with the
TLR ligand resulted in decreased cytokine production when com-
pared to mock-infected cells treated with the same dose of TLR
ligand (Murakami et al., 2010). No mechanism for this apparent
inhibition of cytokine production as a result of HHV-6B infection
was proposed by the authors, however, it is an interesting finding
that suggests an inhibitory role for HHV-6B during latency.
γ-HERPESVIRUSES
EPSTEIN-BARR VIRUS
Epstein-Barr virus (EBV), also known as human herpesvirus
4 (HHV-4), is one of the most ubiquitous pathogens in the
human population, infecting over 90% of the world’s popu-
lation (Cesarman, 2011). EBV infection can lead to multiple
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outcomes, ranging from infectious mononucleosis to cancer,
including Burkitt’s lymphoma and nasopharyngeal carcinoma
(Cesarman, 2011). Several reports have indicated a role for TLR
signaling upon primary EBV infection in multiple cell lines. In
2007, three different TLRs activated by EBV infection in three
distinct cell types were identified. The initial report identifying
a role for TLR signaling during EBV infection found that TLR2
was activated in both human monocytes and HEK-293 cells sta-
bly expressing TLR2 (Gaudreault et al., 2007). TLR2 activation led
to increased NF-κB expression and secretion of the chemokine
CCL2. Activation of TLR2 was confirmed by pre-treating cells
with blocking antibodies to TLR2 prior to EBV infection. NF-κB
levels were significantly decreased in cells pre-treated with block-
ing anti-TLR2 antibodies indicating TLR2 specific recognition in
B cells. Infection of HEK293-TLR2 cells with UV-inactivated EBV
and infection of TLR2 expressing cells pre-treated with phos-
phonoacetic acid (a viral DNA polymerase inhibitor) also led
to increased NF-κB expression, indicating that TLR2 could rec-
ognize intact virions and that stimulation was not dependent
on viral replication, only on binding of EBV to the cell surface
(Gaudreault et al., 2007).
A second report in 2007 indicated that EBV infection of B cells,
the natural reservoir for EBV, led to upregulation of TLR7 and
enhanced B cell proliferation. This was observed for infection of
B cells with both wild type EBV and UV-inactivated EBV (Martin
et al., 2007). Additionally, induction of a dominant negative form
of IRF5 was observed following EBV infection. This is evidence
that not only can EBV activate these innate immune pathways
but that it can also manipulate them. Activation of wild type
IRF5 typically results in tumor suppressive and antiviral activ-
ities, however, EBV specific induction of a dominant negative
IRF5 indicates that the virus is capable of inhibiting the anti-viral
effects of cellular IRF5 (Martin et al., 2007).
In 2009 the EBV dUTPase (BLLF3) was shown to acti-
vate NF-κB specifically through TLR2 (Ariza et al., 2009). In
both HEK293 cells stably expressing TLR2 and human mono-
cyte derived macrophages, proinflammatory cytokine production
(IL-6) and NF-κB activation could be inhibited by treatment
of cells with blocking anti-TLR2 antibody (Ariza et al., 2009).
This was the first report of TLR recognition of a nonstruc-
tural herpesvirus protein leading to proinflammatory cytokine
production.
EBV infection of pDCs, a subset of DCs, that are recognized
as the most prolific producers of type I IFN in response to virus
infection, was shown to result in increased IFN-α production
(Lim et al., 2007). This report used an in vivo humanized mouse
model to show that mice reconstituted with human PBMCs
enriched with pDCs and challenged with EBV showed increased
survival over mice reconstituted with non-enriched PBMCs (Lim
et al., 2007). The increased survival rate was attributed to TLR9
activation of pDCs and the subsequent upregulation of IFN-α.
Activation of natural killer cells (NK) and IFN-γ producing T
cells was also a result of the activated pDCs in the mice recon-
stituted with pDC enriched PBMCs. pDCs along with primary
monocytes were also shown to respond to EBV infection via TLR9
(Fiola et al., 2010). This study showed that treatment of both
monocytes and pDCs with the endosomal acidification inhibitor,
chloroquine, led to decreased levels of secreted proinflammatory
cytokines, e.g., IL-8 (Fiola et al., 2010). Inhibition of TLR9 via
a TLR9-specific ODN compound also led to decreased cytokine
secretion including IFN-α and IL-6, in addition to IL-8 (Fiola
et al., 2010).
In addition to TLR9, EBV infection of pDCs has also been
shown to activate TLR7 signaling. Quan et al. showed that pri-
mary infection of pDCs led to activation of TLR7 and TLR9
leading to increased IFN-α (Quan et al., 2010). Increased IFN-α
was observed following infection with wild-type EBV and UV-
inactivated virions. EBV DNA alone was not able to stimulate
IFN-α production. Pre-treatment of pDCs with chloroquine led
to decreased IFN-α in a dose dependent manner. This evidence,
combined with the UV-inactivation data, indicated that replica-
tion is not required for TLR9 mediated IFN-α production. The
authors also investigated whether EBV-encoded RNAs (EBERs),
small RNAs produced during EBV latency, could stimulate IFN-α
production from pDCs (Quan et al., 2010). pDCs transfected with
EBERs showed increased IFN-α levels, and those levels could be
inhibited with treatment with inhibitory oligonucleotides specific
to TLR7. IFN-α levels were not changed in response to EBERs in
the presence of TLR9 specific inhibitors, indicating a specificity
for TLR7 (Quan et al., 2010).
Recently, B cells undergoing EBV lytic replication were also
shown to stimulate TLR9 (Van Gent et al., 2011). B cells were
infected with increasing amounts of EBV and levels of the activa-
tion marker CD54 were compared to cells treated with the TLR9
agonist, CpG. CD54 increased with increasing amounts of EBV
similarly to treatment with CpG (Van Gent et al., 2011). All of
the above studies indicate how widespread and varied TLR activa-
tion can be and that activation can occur through multiple TLRs
depending on the cell type.
EBV encoded antagonists of TLR signaling and interferon activation
Several EBV proteins have been shown to play a specific role
in TLR signaling. EBV encodes a tegument protein, LF2 that
interacts with IRF7 and suppresses IRF7-mediated IFN-alpha
production (Wu et al., 2009). Additionally, both EBV LMP1 and
the EBV lytic protein BGLF5 have been shown to downregulate
levels of TLR9 by inhibiting TLR9 transcription or inducing TLR9
RNA degradation, respectively (Fathallah et al., 2010; Van Gent
et al., 2011).
KAPOSI’S SARCOMA-ASSOCIATEDHERPESVIRUS
Kaposi’s sarcoma-associated herpesvirus (KSHV), also known
as human herpesvirus 8 (HHV-8), is the etiological of Kaposi
sarcoma and the primary cause of two B cell lymphoprolifer-
ative disorders, primary effusion lymphoma (PEL) and multi-
centric castleman’s disease (MCD) (Chang et al., 1994; Ablashi
et al., 2002). KSHV is also the leading cause of cancer in
HIV infected individuals [reviewed in Henke-Gendo and Schulz
(2004)]. KSHV encodes many proteins capable of manipulating
the host immune system but prior to 2008 there was no pub-
lished data on the activity of TLRs in response to primary KSHV
infection or during the process of reactivation.
Our lab reported the first evidence for KSHV activation of
TLR signaling showing that primary KSHV infection of both
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monocytic leukemia cells (THP-1) and primary human mono-
cytes resulted in increased levels of TLR3 and subsequently
increased IFN-β production (West and Damania, 2008). We
also observed concomitant increases in several key inflamma-
tory cytokines, including CXCL10 and IL-6. Knockdown of TLR3
using shRNA prior to KSHV infection resulted in decreased
IFN-β indicating TLR3 is the primary responder to KSHV
infection in monocytes (West and Damania, 2008). We also
observed increased NF-κB expression following KSHV infection
in HEK293 cells stably expressing TLR3 compared to normal
HEK293 cells (West and Damania, 2008).
Endothelial cells are one of the cell types infected by KSHV. It
was shown in 2008 that KSHV infection led to downregulation
of TLR4 (Lagos et al., 2008). This study showed that two viral
proteins contributed to the decreased levels of TLR4, vIRF1, and
vGPCR. This was the first report of a virus targeting TLR4 for
immune evasion purposes (Lagos et al., 2008).
In 2009, our lab showed that TLRs can also play a critical
role during reactivation of KSHV from latency (Gregory et al.,
2009). We provided the first evidence that TLR stimulation can
lead directly to reactivation of KSHV from latency. Treatment
of KSHV latently infected B cell lines with the cognate agonists
for TLR7/8 resulted in reactivation of KSHV, as observed by lytic
viral gene and protein expression (Gregory et al., 2009). In addi-
tion to synthetic ligands we also showed that exposure of KSHV
latently infected B cells to secondary infection with the known
TLR7 agonist, VSV, led to significant reactivation of KSHV. This
demonstrated for the first time that TLR activation, via a bio-
logically relevant stimulus, could result in reactivation of KSHV
(Gregory et al., 2009).
As described above for EBV and HSV, pDCs are key play-
ers in the innate immune response, particularly in the estab-
lishment of the antiviral state via production of type I IFN.
pDCs have also been shown to be activated in response to
KSHV infection and that activation leads directly to significant
increases in IFN-α production (West et al., 2011). Increased
expression of activation markers CD83 and CD86 was also
observed following KSHV infection of pDCs. It was determined
that increased IFN-α secretion was a direct result of TLR9
activation following KSHV infection (West et al., 2011). pDCs
treated with inhibitory ODNs prior to KSHV infection showed
decreased levels of IFN-α secretion compared with pDCs pre-
treated with control ODNs (West et al., 2011). There was some
residual IFN-α secretion that could be attributed to TLR7 activa-
tion, however, that possibility was not investigated. Interestingly,
unlike many of the previous studies involving herpesvirus acti-
vation of TLR signaling in pDCs, infection with UV-inactivated
KSHV did not result in upregulation of IFN-α, indicating
that TLR9 actually recognizes KSHV DNA upon infection
of pDCs.
KSHV encoded antagonists of TLR signaling and interferon
activation
Several KSHV proteins have been identified as inhibitors of TLR
signaling. Two proteins encoded by KSHV, vIRF1, and vGPCR,
have been shown to downregulate expression of TLR4 (Lagos
et al., 2008). KSHV encodes four different viral IRFs (vIRFs)
which show some similarity to cellular IRFs. Three of these vIRFs
can inhibit the action of cellular IRFs by interacting with them
and preventing their transcriptional function and activation of
IFN-α and IFN-β [reviewed in Jacobs and Damania (2011)].
Another KSHV encoded protein, Orf45, inhibits type I IFN pro-
duction by preventing IRF7 phosphorylation and nuclear accu-
mulation (Zhu et al., 2002, 2010). The immediate early protein,
KSHV Rta/Orf50, has been shown to promote IRF7 ubiquiti-
nation and degradation and also induce the degradation of the
TLR3 adaptor, TRIF (Wang et al., 2005a; Yu et al., 2005; Yu and
Hayward, 2010; Ahmad et al., 2011). KSHV latency associated
nuclear antigen also inhibits expression of IFN-β activation by
IRF3 (Cloutier and Flamand, 2010).
CONCLUDING REMARKS
Herpesviruses are renowned for their ability to modulate host
immune responses upon infection in order to achieve latency.
TLR recognition is the first step in pathogen sensing in the host
and over the last 10 years understanding the role of TLR acti-
vation during virus infection has been a focus of investigation
in the herpesvirus field and has expanded our knowledge as to
how herpesvirus recognition occurs during primary infection.
TLR signaling has also been implicated during reactivation of
herpesviruses, a process essential for these viruses to maintain
themselves in the host.
Defects in TLR expression in patients suffering from diseases
caused directly by herpesvirus infection has also served to shed
light on the role of TLR signaling during virus infection. The
inability of these patients to mount proper immune responses
to virus infection highlights the importance of these signal-
ing pathways during infection and eventual disease progression.
Continued investigation into TLR function in patients suffering
from herpesvirus related disease would provide important in vivo
data that could be used to help discover new targets for treatment
of these viral infections. Already several clinical trials have been
initiated to determine whether TLR agonists could be used as
adjuvants in potential cancer vaccines [reviewed in Gregory et al.
(2011)].
Ongoing investigation into virally encoded inhibitors of TLR
signaling will be critical for discovering new possible treatment
options. At this point there are only a limited number of her-
pesvirus proteins that disrupt TLR signaling, however, based on
the number of known immune modulatory proteins encoded by
herpesviruses [reviewed in Paludan et al. (2011)] it is likely that
there are several uncharacterized viral proteins that play a role in
the manipulation of TLR signaling. Continuing to understand the
contribution of TLR signaling during herpesvirus infection, and
the virus counter response to TLR signaling, will help in design-
ing better vaccine candidates and therapeutics against this family
of viruses.
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